^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Topoisomerase I inhibitor

    Related drugs:
    1d
    A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=348, Not yet recruiting, Akeso
    New P2 trial
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • Idafang (ivonescimab)
    1d
    HELIX-ICC: mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=5, Terminated, OHSU Knight Cancer Institute | Active, not recruiting --> Terminated; change in standard-of-care systemic therapy
    Trial termination
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    1d
    A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    New P2 trial
    1d
    A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=187, Active, not recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Hetronifly (serplulimab) • tambotatug pelitecan (RG6919)
    1d
    Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer. (PubMed, Future Oncol)
    In pooled analyses from TROPION-Lung01 and TROPION-Lung05, Dato-DXd achieved an objective response rate of ~45% and a median duration of response of 6.5 months, which compares favorably with historical outcomes with docetaxel. Dato-DXd is being evaluated in combination with osimertinib in the first-line and post-osimertinib settings, following encouraging activity in the phase II ORCHARD platform trial evaluating therapeutic strategies for EGFR-TKI-resistant disease...Current research aims to elucidate the mechanisms underlying these toxicities and to identify modifiable risk factors to further improve tolerability. The biological mechanisms contributing to the differential efficacy of Dato-DXd are also under investigation and may further inform its clinical role.Expert opinion: Determining how best to integrate Dato-DXd within existing treatment sequences has the potential to meaningfully address persistent unmet needs in EGFR-mutated NSCLC.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • docetaxel • Datroway (datopotamab deruxtecan-dlnk)
    1d
    Analysis of adjuvant chemotherapy efficacy based on GLUT1 expression levels after radical resection of pancreatic cancer (PubMed, Zhonghua Wai Ke Za Zhi)
    Subgroup analysis demonstrated that among patients receiving mFOLFIRINOX or gemcitabine-based combination regimens as adjuvant chemotherapy, both DFS and OS were significantly better in the low GLUT1 expression group compared with the high expression group (all P<0.05). GLUT1 expression level affects adjuvant chemotherapy efficacy after radical resection of pancreatic cancer, and its high expression is an independent adverse prognostic factor.
    Journal
    |
    SLC2A1 (Solute Carrier Family 2 Member 1)
    |
    gemcitabine • irinotecan
    2d
    TRIBE: An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC (clinicaltrials.gov)
    P3, N=140, Not yet recruiting, Fudan University
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811)
    2d
    SKB264 Plus Goleirex in Advanced KRAS G12C-Mutant NSCLC: A Phase II Study (clinicaltrials.gov)
    P2, N=43, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Jiataile (sacituzumab tirumotecan)
    2d
    Dynasty-Breast01: A study comparing DB-1303 with T-DM1 in the treatment of HER2-positive unresectable/metastatic breast cancer patients who had previously received trastuzumab and taxane therapy. (clinicaltrials.gov)
    P3, N=228, Active, not recruiting, Yingen Biopharmaceutical (Suzhou) Co., Ltd. | -> Active, not recruiting | Phase classification: PN/A --> P3
    Enrollment closed • Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Kadcyla (ado-trastuzumab emtansine) • trastuzumab pamirtecan (BNT323)
    2d
    BL-B01D1-303: A Phase III clinical trial comparing BL-B01D1 with physician-selected chemotherapy regimens (last line) in patients with recurrent or metastatic nasopharyngeal carcinoma who had previously received PD-1/PD-L1 monoclonal antibody therapy and failed at least two lines of chemotherapy. (clinicaltrials.gov)
    P3, N=386, Active, not recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | -> Active, not recruiting | Phase classification: PN/A --> P3
    Enrollment closed • Phase classification
    |
    PD-L1 (Programmed death ligand 1)
    |
    gemcitabine • docetaxel • capecitabine • izalontamab brengitecan (BL-B01D1)
    2d
    TQB2102-Ib-01: Evaluation of a Phase Ib clinical trial of injectable TQB2102 in recurrent/metastatic breast cancer (clinicaltrials.gov)
    P1, N=150, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | -> Recruiting | Phase classification: PN/A --> P1
    Enrollment open • Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 expression • HER-2 underexpression
    |
    TQB2102
    2d
    Phase Ib/II clinical study of BL-M07D1 in patients with HER2-expressing recurrent or metastatic gynecological malignancies (clinicaltrials.gov)
    P1/2, N=138, Recruiting, Chengdu Bailidote Biopharmaceutical Co., Ltd. / Sichuan Baili Pharmaceutical Co., Ltd. | -> Recruiting | Phase classification: PN/A --> P1/2
    Enrollment open • Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    trastuzumab brengitecan (BL-M07D1)